Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
16.2M
-
Shares change
-
-369K
-
Total reported value, excl. options
-
$85.7M
-
Value change
-
-$2.79M
-
Put/Call ratio
-
0.15
-
Number of buys
-
14
-
Number of sells
-
-34
-
Price
-
$5.29
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q3 2021
68 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q3 2021.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.2M shares
.
Largest 10 shareholders include Ikarian Capital, LLC (2.54M shares), Bain Capital Life Sciences Investors, LLC (2.12M shares), AIGH Capital Management LLC (1.66M shares), ORBIMED ADVISORS LLC (1.37M shares), VANGUARD GROUP INC (934K shares), BVF INC/IL (848K shares), Altium Capital Management LP (805K shares), Sio Capital Management, LLC (805K shares), AXA S.A. (590K shares), and Monashee Investment Management LLC (561K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.